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Abstract
Common alkylating antitumor drugs, such as temozolomide, trigger their cytotoxicity by
methylating the O6-position of guanosine in DNA. However, the therapeutic effect of these
drugs is dampened by elevated levels of the DNA repair enzyme, O6-methylguanine DNA
methyltransferase (MGMT), which directly reverses this alkylation. As a result, assessing
MGMT levels in patient samples provides an important predictor of therapeutic response;
however, current methods available to measure this protein are indirect, complex and slow.
Here we describe the design and synthesis of fluorescent chemosensors that report directly
on MGMT activity in a single step within minutes. The chemosensors incorporate a fluoro-
phore and quencher pair, which become separated by the MGMT dealkylation reaction,
yielding light-up responses of up to 55-fold, directly reflecting repair activity. Experiments
show that the best-performing probe retains near-native activity at mid-nanomolar concen-
trations. A nuclease-protected probe, NR-1, was prepared and tested in tumor cell lysates,
demonstrating an ability to evaluate relative levels of MGMT repair activity in twenty min-
utes. In addition, a probe was employed to evaluate inhibitors of MGMT, suggesting utility
for discovering new inhibitors in a high-throughput manner. Probe designs such as that of
NR-1 may prove valuable to clinicians in selection of patients for alkylating drug therapies
and in assessing resistance that arises during treatment.
Introduction
Alkylating agents are used as chemotherapeutic drugs to treat multiple cancers, including
gliomas, melanoma, and Hodgkin’s disease [1]. These drugs induce cytotoxicity by forming
covalent adducts with DNA. For example, temozolomide, a drug commonly used to treat glio-
blastoma, is a prodrug that spontaneously breaks down to form a methyldiazonium cation [2].
This highly reactive cation methylates multiple sites on DNA, including the N3-position of
adenine and the N7 and O6 positions of guanine [2]. Among these alkylated products, cytotox-
icity is mainly mediated by methylation at guanine O6 in DNA (O6-MedG). Polymerases mis-
incorporate T opposite O6-MedG during DNA replication to generate a O6-MeG-T mismatch,
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which frequently leads to mutations and cellular dysfunction, and can ultimately lead to cancer
cell death because of repeated unproductive processing by the DNAmismatch repair pathway
[3,4].
A limiting factor in the effectiveness of drugs such as temozolomide is the development of
tumor resistance. It is well established that resistance can result from upregulation of the repair
protein O6-methylguanine-DNA-methyltransferase (MGMT, also denoted AGT) [5]. MGMT
is a DNA repair protein that employs a cysteine residue to attack the O6-methyl group directly,
leaving behind repaired guanine. As a result of this action, the protein is permanently alkylated
(inactivated) and is marked for proteasomal degradation. MGMT is often overexpressed in
tumors, particularly after an initial round of treatment, resulting in the reversal of the O6-alkyl-
ation and dampening the therapeutic effect of alkylating drugs [1, 6]. Alkylating drugs are
therefore more effective in cancers that have low levels of MGMT, and for this reason, MGMT
itself has become attractive as a drug target, since depleting its activity enhances the potency of
alkylating drugs [1,7]. Thus, the level of activity of the MGMT repair system is important in
diagnosis, prognosis and treatment of cancer, particularly for patients with brain tumors and
melanomas [6]. In addition, temozolomide has shown significant therapeutic promise in recent
clinical studies of acute myeloid leukemia (AML), a finding that also requires knowledge of
MGMT activity [8]. Measuring MGMT repair activity in these diseases is valuable in predicting
patient responses to alkylating drugs prior to treatment, guiding personalized therapies; in
addition, monitoring activity over the course of therapy can be beneficial to evaluate any
acquired resistance to the drug [1, 5].
Common methods to measure MGMT activity are indirect, complex and time-consuming.
The most widely adopted approach is to use methylation-specific PCR to measure the degree
of promoter methylation of CpG sequences for theMGMT gene [5,9]. However, due to its indi-
rect nature, DNAmethylation status correlates only moderately well with MGMT activity [10].
This weak correlation leads to difficulties in predicting resistance to anticancer alkylating drugs
[10]. Another approach has used antibodies to quantify MGMT in an ELISA-based assay [11].
However, this method requires extensive washing steps and measures the amount of protein,
not activity. Another common method uses a radiolabeled DNA substrate, whereby the degree
of repair can be followed by transfer of the radioactive methyl group to the MGMT protein
using procedures to separate protein and DNA [9,12]. Alternatively, 32P-labeled or fluoro-
phore-labeled dsDNA probes containing the O6-MedG substrate have been employed; upon
repair, a restriction enzyme cleavage site is generated and the degree of repair is followed by
detection of DNA fragments by gel electrophoresis [13,14]. Although these methods do mea-
sure protein activity, the numerous steps required post-repair and the requirement for gel elec-
trophoresis limit their use for rapid and/or high throughput assessments of MGMT activity. In
this regard, a few fluorescence-based assays have been developed, aiming for simple and fast
detection of MGMT. For example, Tintoré et al. [15] used an aptamer containing an O6-MedG
lesion, as well as a fluorophore and a quencher at opposite ends of the sequence. A quadruplex
structure is formed only upon MGMT repair, which results in a decrease in fluorescence as the
fluorophore and quencher are brought in closer proximity. Although the assay does not require
gel electrophoresis or isolation of reaction products, the reported signal changes were small
(<2-fold), and measurements in whole cell lysates were not demonstrated [15]. Robinson et al.
[16] developed an assay using a fluorophore labeled-O6-benzylguanine pseudosubstrate,
whereby incubation with MGMT results in transfer of the fluorophore to the protein. Detec-
tion in whole cell lysates was demonstrated; however, separation of unreacted probe by thin
layer chromatography was required for quantifying activity [16].
As a result of these limitations, and because of the clinical importance of measuring MGMT
activity, a simple fluorescence-based assay that rapidly reports directly on activity with high-
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signal to noise within cell extracts could serve as a valuable tool for researchers and clinicians
associating MGMT with cancer prognosis and treatment.
Results
Design and Synthesis of Fluorogenic MGMT Probes
To design probes that can report on MGMT activity, we first focused on a developing a strategy
for coupling fluorescence to the bond-breaking step that occurs during repair of O6-alkylgua-
nine. Previous work on MGMT has established that the enzyme can repair an alternative sub-
strate, O6-benzylguanine (BG), within a DNA oligonucleotide [17]. Notably, repair activity was
found to be more efficient with BG than with its native O6-methylguanine substrate; the repair
mechanism is the same except that the larger benzyl group is transferred to the MGMT active
site. Subsequent studies have shown that modifications on the benzyl moiety, in particularly at
the para position, do not alter enzymatic activity significantly [18]. With this in mind, we envi-
sioned that a short DNA oligomer containing the BG substrate but synthetically modified on
the benzyl group with a quencher (Fig 1), might still act as a good substrate for MGMT and
simultaneously as a quencher for a neighboring fluorophore. In the presence of MGMT, the
substrate would be expected to transfer its benzyl-quencher group to the MGMT active site,
separating it from the fluorophore, and resulting in a fluorescence light-up signal from the
repaired probe. Since the fluorescence signal is produced stoichiometrically with repaired gua-
nine, such a probe would directly and quantitatively respond to MGMT activity in real time. It
should be noted that while SNAP-tag probes (employing fluorophore-modified BG) have been
developed that also transfer modified benzyl groups to a protein, they bind poorly to wild-type
MGMT [19]. Based on the above reports, we reasoned that repair of BG within a DNA oligo-
mer would result in strong binding and fast repair by native MGMT.
Our synthesis strategy (Fig 2) relied on modifying the BG nucleoside such that the final build-
ing block can be simply incorporated into oligonucleotides by solid phase DNA synthesis. The
DABCYL quencher was chosen since it can efficiently quench nearby fluorophores by FRET
and/or static quenching mechanisms [20]. The first half of the synthesis involved reacting com-
mercially available (4-aminomethyl-phenyl)-methanol with NHS-ester DABCYL to generate
compound 6 in high yields (see Supporting Information (SI) text for details). The second half
entailed fully protecting 2’-deoxyguanosine by TBDMS and isobutyryl protection to provide
compound 7. Mitsunobu coupling of 6 and 7 produced quencher-substituted nucleoside 8 in
50% yield. Finally, deprotection of TBDMS followed by standard 5’-OH tritylation and 3’-OH
phosphoramidite derivatization yielded the final monomer for DNA synthesis (11, Fig 2).
Incorporating 11 during DNA synthesis, we constructed several candidate MGMT probes
to act as potential substrates for the enzyme. Probe designs were based on multiple concepts:
Fig 1. Design principle for a DNA-based chemosensor that reports on MGMT activity. A short modified DNA oligomer (see Table 1) contains anO6-
benzylguanine nucleoside modified with a quencher dye. Fluorescence from a neighboring fluorophore (X) is initially quenched as a result of the proximity.
When MGMT repairs the alkylated base, the benzyl-quencher group is transferred to the enzyme’s active site and fluorescence emission increases.
doi:10.1371/journal.pone.0152684.g001
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first, MGMT has been shown to have no preference for repairing damage in ssDNA versus
dsDNA [18], thus we designed the molecules to be active in single-stranded form. Second,
MGMT has been reported to repair BG efficiently within short oligonucleotides greater than
trimer in length [21], and so our candidate compounds were prepared in 4–5 nt lengths. Third,
we envisaged applications in vitro and in cell lysates, and so modifications to enhance cell per-
meability were not carried out, since the modification might also be deleterious to enzyme
activity. Lastly, MGMT displays no known selectivity in the DNA sequence for its repair activ-
ity, nor any strong preference for the positioning of the BG site within the DNA, providing the
alkylated nucleoside is not incorporated directly at the 3’ end [22]. Thus our probe designs con-
tained the monomer 11 at internal positions.
To complete the probe design, we chose a series of fluorophores that could be quenched effi-
ciently by the nearby DABCYL-BG group. As one dye, perylene deoxynucleoside [23] was cho-
sen since its cyan emission overlaps well with the absorption spectrum of DABCYL. In that
case we would expect FRET-based quenching to occur by DABCYL-BG prior to MGMT repair.
We also tested a series of longer-wavelength dye monomers, including FAM-dT, TAMRA-dT
and Cy3 dyes, all of which can be quenched by DABCYL when placed in close proximity [20].
After standard oligonucleotide synthesis, probes were purified by HPLC and characterized by
mass spectrometry (Table A in S1 File). Table 1 summarizes the MGMT probes synthesized
along with their photophysical properties.
Fig 2. Synthesis of Dabcyl-BG nucleoside phosphoramidite 10, which was used as amonomer in preparation of chemosensors 1, 2, 3 and 4.
doi:10.1371/journal.pone.0152684.g002
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Evaluation of Probes in Vitro
To test whether the probes could act as MGMT substrates and produce fluorescence responses
upon repair, in vitro assays were carried out with purified human recombinant enzyme. Probes
were incubated in a 1:1 stoichiometric ratio with MGMT (100 nM, 37°C) and fluorescence was
monitored over time. Signals were found to increase for all probes, with maximum fluorescence
reached in ca. 3–10 min (Fig 3). To confirm that reaction of the probe with MGMT was the ori-
gin of the fluorescent signal, crude reaction mixtures were analyzed by MALDI-MS. The data
clearly showed the appearance of fully repaired oligonucleotides containing native guanine and
lacking the DABCYL-benzyl moiety (Figure A in S1 File). This confirms that MGMT can rec-
ognize a quencher-modified BG and repair the lesion by transferring the O6 group from the
substrate.
Table 1. Sequences and optical properties of chemosensors.
Chemosensor Sequence a Ex. (nm) Em. (nm) Fold-change
1 A-dTFAM–GDAB-A 496 520 55 ± 5.0
2 Cy3-GDAB-A-A-A 550 560 30 ± 2.0
3 A-dTTMR-GDAB-A 565 580 12 ± 1.2
4 A-E-GDAB-A 454 475 50 ± 2.0
a GDAB denotes the Dabcyl-BG nucleoside
doi:10.1371/journal.pone.0152684.t001
Fig 3. Performance of modified DNA chemosensors containing the Dabcyl-BG nucleoside. Fluorescence spectra showing the overall fold-changes in
intensity observed when comparing fluorescence measured before (dashed line) and after (solid line) addition of purified MGMT protein are shown at left of
each figure. Time courses (on the right) show time-dependent fluorescence increases immediately after addition of enzyme. Final probe and MGMT
concentrations were 100 nM. Assays were run at 37°C in 70 mMHEPES buffer pH 7.8 containing 5 mM EDTA, 1 mM dithiothreitol and 50 μg/ml BSA. (A)
chemosensor 1 containing dTFAM, (B), chemosensor 2 containing Cy3, (C), chemosensor 3 containing dTTMR and (D), chemosensor 4 containing perylene
nucleoside. Measurements were repeated 3 times. Standard deviations are provided in Table 1.
doi:10.1371/journal.pone.0152684.g003
Fluorescent Sensors for MGMT
PLOSONE | DOI:10.1371/journal.pone.0152684 April 1, 2016 5 / 15
Quantitative fluorescence measurements allowed us to evaluate the signaling performance
of these probes. The data revealed that the largest increase in signal upon reaction occurred
with chemosensor 1 (FAM-substituted), resulting in a 55-fold change in green fluorescence
after MGMT repair (Table 1). The reaction with this probe also occurred the fastest of the
three probes, with complete repair achieved in ~3 min. We measured a Km of 58 ± 17 nM
(Figure B in S1 File), which is in the reported range for naturally substituted oligonucleotides
containing BG (ED50 = 10–90 nM)[21]. Our measured value of kcat (0.011 s
-1) is moderately
lower than the reported values for native O6-MedG (0.035–0.39 s-1) [24]. Thus we conclude
that the multiple synthetic modifications in the probe have relatively little adverse effect on its
ability to act as a substrate and reporter.
Evaluating MGMT Inhibitors
We assessed fluorescein probe 1 for utility in testing inhibitors because of its efficient photo-
physical and biochemical performance relative to the other probes. Inhibitors of MGMT are
currently being employed in clinical trials to improve the efficacy of temozolomide [7]. A sim-
ple assay to monitor MGMT activity would allow for direct evaluation of current inhibitors
and/or the discovery of new inhibitors with different pharmacologic properties. To test the
effectiveness of probe 1 in this application, we first employed the known inhibitor BG (free
nucleobase), which inhibits MGMT by acting as a pseudosubstrate. BG is a moderately potent
inhibitor with a reported IC50 of 200 nM [25]. MGMT was incubated first with 25–800 nM of
BG at 37°C. After 10 min, an equimolar amount of probe was added and fluorescence was
acquired after signals no longer changed. In comparison to the positive control (no inhibitor),
the overall fluorescence change decreased with increasing concentrations of BG, with a mea-
sured IC50 = 176 ± 46 nM (Fig 4 and Figure C in S1 File). Next we employed the inhibitor
PaTrin-2; this second compound also acts as a pseudosubstrate for MGMT but is considerably
more potent than BG [25]. Pre-incubation of MGMT with 5–200 nM PaTrin-2, a lower con-
centration range, led to decreases in fluorescence with a measured IC50 = 54 ± 18 nM. The data
establish that probe 1 can be used to evaluate inhibitors and measure their relative potencies.
Differentiating MGMT Activity in Cell Lysates
Current methods for measuring MGMT activity in cellular samples require several steps involv-
ing lengthy workups [26]. Hence, we next tested whether FAM probe 1 could simplify the assay
of MGMT activity in such samples. We first tested the selectivity of our probe for MGMT by
measuring fluorescence in mammalian whole-cell extracts. To reduce possible background sig-
nals generated by nuclease activity, the probe was modified to contain 2’-OMe groups and phos-
phorothioate linkages. The combination of both modifications have been shown to increase
resistance of oligonucleotides to nuclease activity [27]. In vitro tests confirmed that this nuclease-
resistant probe (NR-1) behaved similarly to the unmodified probe 1 (Figure D in S1 File).
The probe NR-1was first tested in TK6+MGMT (TK6+) lymphoblastoid cell lysates, which
had been previously complemented with an MGMT expression cassette to increase MGMT activ-
ity from otherwise undetectable levels [28]. Incubation with 50 nM probe resulted in an immedi-
ate increase in fluorescence with signals plateauing after 20 min at 37°C (Fig 5). By using the
overall fluorescence fold-change, the amount of active MGMT was determined to be 2.9 pmol/mg
(see Materials andMethods and Figure E in S1 File for calculation). To test whether this change is
a result of MGMT repair, we pretreated TK6+ lysates with 2.5 μM of the potent MGMT inhibitor
PaTrin-2. In this case, the NR-1 probe gave no significant changes in fluorescence (Fig 5 and
Figure F in S1 File). We then generated lysates from a TK6- cell line, in which promoter hyper-
methylation prevents expression of the nativeMGMT gene. Again, no detectable changes in
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fluorescein fluorescence were observed (Fig 5 and Figure F in S1 File). Thus, these experiments
demonstrate that the NR-1 probe is highly selective for the MGMT enzyme, and that changes in
MGMT activity in cell lysates can be readily measured in a few minutes in a fluorescence cuvette.
Next we tested whether probe NR-1 can be used to differentiate levels of MGMT activity in
different tumor cell lysates. We chose the breast cancer cell line MCF-7, which is known to
have high levels of MGMT (3.24 pmol/mg of protein) [29], and two colon cancer cell lines,
HT-29 (1.14 pmol/mg of protein) and SW48 (<0.05 pmol/mg of protein), known to have
lower levels of activity [29,30]. We generated whole cell lysates and measured fluorescence
time courses after addition of 50 nM probe. Once a steady signal was reached (40 min), spectra
were acquired and corrected for background probe fluorescence and total protein content (see
Methods). The resulting fluorescence levels would be indicative of MGMT activity, and in a rel-
ative sense, activity from different lysates could be compared (Fig 6). From the three cell lines
we observe the highest MGMT activity fromMCF-7 (2.6 ± 0.20 pmol/mg), followed by HT-29
(1.4 ± 0.35 pmol/mg) and the lowest from SW48 (0.61 ± 0.17 pmol/mg) (Fig 6). This trend is
in good general agreement with previously reported levels of MGMT in these cell lines [29,30].
Discussion
Our experiments show that probe NR-1 enables exceedingly simple real-time measurement of
MGMT-mediated repair by fluorescence, and thus offers a method that is much simpler, faster
Fig 4. Evaluation of MGMT inhibitors with chemosensor 1. Incubation of purified MGMT enzyme with the
inhibitors BG and PaTrin-2 led to a concentration dependent decrease in observed final fluorescence
intensity, indicative of MGMT inhibition. MGMT (10 nM) was incubated with inhibitor for 10 min at 37°C in 70
mMHEPES buffer (pH 7.8) containing 5 mM EDTA, 1 mM dithiothreitol and 50 μg/ml BSA. Final fluorescence
was acquired 10 min after addition of probe (10 nM). Data were normalized to measurements without
inhibitor. Each data point is the average of 3 measurements.
doi:10.1371/journal.pone.0152684.g004
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and more directly relevant to repair activity than current methods. It is well established that
high MGMT activity in tumor cells confers resistance to alkylating agents [5]. As a result, the
MGMT status within tumors has become a clinically important predictor of a patient’s
response to chemotherapeutic drugs. Because of the relative difficulty in measuring protein
activity directly by prior methods, the current method of choice for determining MGMT activ-
ity levels is measuring promoter CpG methylation for theMGMT gene [9]. Although correla-
tions have been found, several studies have shown discrepancies between DNA methylation
and MGMT levels [10]. For example, Kreth et al. [31] measuredMGMTmRNA expression lev-
els and found that 25% of glioblastoma samples showed an inverse correlation with promoter
methylation. Lalezari et al. [32] also observed an inverse correlation using immunohistochem-
istry staining compared to promoter methylation in 44% of patient samples. These studies
implicate other possible mechanisms for regulation beyond the level of transcription and as a
consequence, the correlation between promoter CpG methylation and MGMT activity breaks
down in a substantial number of patients. Therefore, measuring activity directly, as NR-1 does,
may provide a more clinically relevant assessment of MGMT [9,33]. The current trend toward
increasing adoption of fluorescence assays in clinical applications [34,35] also suggests utility
for the new probes.
To date, only a few reports of probes for MGMT activity have been described. Damoiseaux
et al. [36] reported an oligonucleotide containing BG synthetically modified with biotin. The
biotin moiety is transferred to the active site of MGMT and is sequentially immobilized on
streptavidin-coated wells and detected by immunofluorescence staining. Although the method
selects for active enzyme, subsequent reading out of activity still requires multiple steps. In
addition, the probe design has not been tested with cell lysates. A report of a fluorescent probe
was described by Li et al. [37] wherein BG was modified with a fluorophore and used in the
Fig 5. Selectivity for sensing MGMT activity.When chemosensor NR-1 was added to TK6+ cell lysates
(high amounts of MGMT) an immediate increase in fluorescence was observed. Addition of probe to TK6- cell
lysates (MGMT knockout) or pretreating TK6+ with 2.5 μM inhibitor PaTrin-2 (10 min, 37°C) led to no change
in fluorescence with time. Final probe concentration was 50 nM and total protein used was 200 μg. Data was
acquired at 37°C. Measurements were repeated 3 times. Standard deviations are provided in Figure G in S1
File.
doi:10.1371/journal.pone.0152684.g005
Fluorescent Sensors for MGMT
PLOSONE | DOI:10.1371/journal.pone.0152684 April 1, 2016 8 / 15
free-base form to label active MGMT. However, the molecular design lacks a mechanism for
fluorescence change upon labeling. Thus it would require development of a method to separate
the reacted probe and enzyme from one another prior to fluorescence measurement, compli-
cating its use and prohibiting its application in real-time assays for MGMT activity. During the
completion of this manuscript, Yu et al. [38] reported BG modified with a fluorescent molecu-
lar rotor that increased in fluorescence upon labeling MGMT. However, fluorophore-labeled
BG (or SNAP-tag probes) are poor substrates for wild-type MGMT [19,39] and as a conse-
quence the fluorescence response with enzyme was slow, requiring high concentrations of
probe (5 μM) to produce signals on a timescale of hours.
In contrast to the above approaches, NR-1 and the other current probes are built from a
DNA scaffold, the enzyme’s native target, which allows for the incorporation of fluorophores/
quenchers to assay repair directly, and allows them to retain the superior activity of DNA sub-
strates. Since the enzyme tolerates modifications on the benzyl substrate, the incorporation of a
quencher group enables large fluorescence responses to occur upon DNA repair. Current prac-
tice measures MGMT from lysates or fixed cells generated from homogenized biopsied tumor
tissue [9,33]. The current data show that NR-1 can measure MGMT directly from lysates from
multiple tumor cell lines in a timescale of minutes with only 50 nM probe (Fig 6). The single-
step/direct design of probe NR-1may in principle provide rapid and quantitative measure-
ments of MGMT activity in clinical samples from solid tumors.
In addition to solid tumors, a recent clinical study showed substantial promise for the use of
temozolomide in the treatment of acute myeloid leukemia [8]. Patients were selected by their
Fig 6. Differential detection of MGMT activity in tumor cell lysates.Chemosensor NR-1 was added to
whole cell lysates generated fromMCF-7, HT-29 and SW48 cell lines. Final spectra were acquired after a
plateau in fluorescence was observed. Spectra were then subtracted from background probe fluorescence
(probe alone spectrum) and normalized by total amount of protein in order to compare activity levels. Final
probe concentration was 50 nM. Data were acquired at 37°C. Measurements were repeated 3 times.
Standard deviations are provided in Figure G in S1 File.
doi:10.1371/journal.pone.0152684.g006
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levels of MGMT; the authors employed a Western blot method to measure MGMT protein lev-
els. Significantly, they reported difficulties in enrolling patients due to the slow nature of the
assay, which required one week to obtain results. In contrast, the current chemosensor design
offers a one-step optical measurement of protein activity from cells, yielding full quantitative
responses in a few minutes.
Inhibiting MGMT with pseudosubstrates such as BG has been found to increase tumor sen-
sitivity to alkylating agents [7]. Co-administering inhibitors with alkylating drugs has therefore
become a clinically investigated strategy for cancer treatment [7]. Using the current chemosen-
sor design, we were able to quantify inhibitory activity of two clinically approved MGMT
inhibitors (Fig 4). The measured potency of these inhibitors was in good correlation with previ-
ous reports [18,25,40]. Furthermore, in light of the ongoing search for new MGMT inhibitors
[41–43], chemosensors such as the current ones could be readily employed for high-through-
put screening to identify new lead structures.
Lastly, it is known that polymorphisms in theMGMT gene can generate protein mutants
that are resistant to free BG but still retain activity on BG-DNA [1,21,44]. Studies have shown
that resistant forms may be acquired during BG or alkylating agent exposure [45–47]. It seems
possible that DNA-based fluorogenic probes such as NR-1may be capable of characterizing
activity from such MGMTmutants, and thus could be used to monitor this class of mutational
resistance acquired during the course of therapy.
Materials and Methods
DNA synthesis
dTFAM, dTTMR, and Cy3 phosphoramidites were purchased from Glen Research. All oligonu-
cleotides were synthesized on a model 394 DNA/RNA synthesizer (Applied Biosystems) with a
DMT-off program. Fluorescent monomer E was prepared as described [48]. GDAB phosphora-
midite (compound 11) was dissolved in anhydrous acetonitrile:dichloromethane (50:50) for
DNA synthesis. The coupling of each monomer used standard 30-to-50 cyanoethyl phosphora-
midite chemistry with 999 s coupling times for dTFAM, dTTMR, Cy3, GDab and E. Average cou-
pling yields for the newly synthesized GDAB was 95%. All chemosensors were synthesized on
1 μmol 3’PO3 CPG columns except for NR-1, which was made on a dA-CPG column. The
nuclease-resistant chemosensor NR-1 was synthesized using 2’-O-methyladenosine phosphor-
amidite and Sulfurizing Reagent II (Glen Research) with a 300s sulfurization time. Chemosen-
sors 1, 2, 4 and NR-1 were deprotected using 10% 1,8-Diazabicycloundec-7-ene (DBU) in
anhydrous methanol for 10 days at room temperature to ensure complete removal of the gua-
nine isobutyryl group. The mixtures were then dried by SpeedVac. Chemosensor 3 containing
dT-TMR was deprotected in potassium carbonate (0.05 M) in methanol for 10 days, neutral-
ized with glacial acetic acid, and then dried by SpeedVac. Complete removal of the isobutyryl
group was not observed (~25%), but the product could be efficiently separated by HPLC
purification.
Purification of Chemosensors
All oligonucleotides were purified by HPLC on semi-preparative C18 column (length = 250
mm, ID = 10.0 mm) using triethylammonium acetate (TEAA) buffer (0.1M, pH 7.0) and aceto-
nitrile. The following gradient was used: 5–95% acetonitrile at 1.5 ml/min flow in 35 min. The
collected products were dried by SpeedVac, resuspended in water and stock solutions stored
frozen at -20°C. The chemosensors were identified by MALDI-TOF (Table A in S1 File). The
concentration of chemosensor 1 was measured in phosphate saline buffer pH 7.0, using the
sum of the extinction coefficients for dabcyl and fluorescein at 500 nm (95 600 M-1cm-1). The
Fluorescent Sensors for MGMT
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concentrations of chemosensor 2 and 3 were measured in acetonitrile using the extinction coef-
ficients at 550 nm (135 000 M-1cm-1) and 565 nm (89 000 M-1cm-1), respectively. The concen-
tration of chemosensor 4 was measured in phosphate saline buffer pH 7.0 using the extinction
coefficient of DABCYL at 480 nm (32 000 M-1cm-1). All chemosensors were stored at -20°C
and were stable for at least 6 months.
Fluorescence-based MGMT Assays
Purified recombinant human MGMT (His-tagged, expressed in E.Coli) was purchased from
Creative BioMart. All assays were carried out at 37°C in 70 mMHEPES buffer (pH 7.8) con-
taining 5 mM EDTA, 1 mM dithiothreitol and 50 μg/ml BSA. Fluorescence was performed in a
quartz cuvette. Background fluorescence spectra were acquired after the probe (100 nM) had
been incubated for 5 min at 37°C. The time course of fluorescence activation was recorded
immediately after addition of MGMT (100 nM). Excitation and emission are listed in Table 1.
Slit widths were 3 nm and 2 nm for excitation and emission, respectively. Final fluorescence
spectra were acquired once a plateau in the fluorescence time course was observed.
For evaluating inhibitors, MGMT (10 nM or 100 nM) was preincubated with O6-benzylgua-
nine (Santa Cruz Biotechnology) (25–800 nM) or PaTrin-2 (Cayman Chemical) (5–200 nM)
for 10 min at 37°C in a 96-well plate. The final amount of DMSO did not exceed 0.5%. Fluores-
cence was recorded on a Thermo Fluoroskan Ascent FL fluorescent plate reader (Ex. 485 nm,
Em. 538 nm). Chemosensor 1 (10 or 100 nM) was added and final fluorescence emission at
538 nm was acquired once a plateau was reached. All spectra were normalized to the spectrum
obtained after the addition of probe to MGMT that had been preincubated for 10 min with
0.5% DMSO.
Mammalian cell extracts
HT-29, SW48 andMCF-7 cell lines were purchased from ATCC. TK6+ and TK6- were provided
by the Leona Samson lab (MIT). HT-29 and SW48 were grown inMcCoys 5Amodified medium
supplemented with fetal bovine serum (10%), penicillin (100 UmL-1) and streptomycin (100 μg
mL-1). TK6+ and TK6- were grown in DMEM supplemented with fetal bovine serum (15%),
penicillin (100 U mL-1) and streptomycin (100 μg mL-1). All cell lines were cultured in a humidi-
fied incubator at 37°C with 5% CO2. Cell extracts were obtained by the protocol adapted from
Folco et al. [49], with the following changes: the cells (~2 x 106) were collected by trypsinization
at 37°C with 5% CO2; Roche complete mini EDTA-free tablets were used for protease inhibition;
the cells were lysed by passing 15 times through a 21 gauge needle and 10 times through a 16
gauge needle. The nuclear fraction was pooled with the cytosolic fraction. Extractions were parti-
tioned in 100 μL aliquots and stored at -80°C until used. Final buffer was: 10 mMHEPES (pH
7.9), 1.5 mMMgCl2, 10 mMKCl, 0.5 mM dithiothreitol with 5% glycerol and 1x protease inhibi-
tor. Total protein concentration was determined by a Bradford assay.
Fluorescence Assays with Extracts
Fluorescence assays with cell extracts were performed in the buffer used during lysis (10 mM
HEPESpH 7.9, 1.5 mMMgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 5% glycerol, 1x protease
inhibitor) plus the addition of 5 mM EDTA. Fluorescence was acquired with chemosensor NR-
1 alone (50 nM) and lysates alone to correct for background fluorescence. After addition of
probe (50 nM) to lysates, fluorescence at 520 nm was acquired with time. Once a steady signal
was reached (~40 min), final spectra was measured and subtracted from background spectra.
The corrected spectra was then divided by the amount of total protein used in the assay. Any
fluorescence signal observed on the final spectra represents MGMT activity.
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Calculation of MGMT Activity in Extracts
MGMT activity was calculated as follows: The final fluorescence fold-change by NR- 1 in cell
lysates was determined using 200 μg of TK6- lysate with 50 nM probe and addition of various
amounts of purified MGMT (6–75 nM), followed by incubation for 1 h at 37°C in a 60 μL
cuvette to generate a calibration curve (Figure E in S1 File). The overall fold-change was then
measured following incubation of 50 nM NR-1 with 1 mg protein extract from TK6+, MCF-7,
HT-29 or SW48 using the same assay conditions. Fold change in fluorescence was then divided
by the total mg of lysates used in the assay. Using the resulting normalized fold change per mg
lysate, the concentration of MGMT (pmol MGMT per mg lysate) was then calculated from the
calibration curve. Note: the fold changes observed were all greater than 1.5-fold but less than
10-fold to remain within the linear range of the assay between 6 and 50 nMMGMT. For MCF-
7, HT-29 and SW48, 1 mg of lysate was used to generate signal to stay within the linear range
of the calibration curve. For TK6+, 200 μg of lysates were used to stay within the linear range of
the calibration curve.
Kinetic Parameters
Michaelis–Menten curve was generated by preincubating MGMT (25 nM) in 70 mMHEPES
buffer (pH 7.8) containing 5 mM EDTA, 1 mM dithiothreitol and 50 μg/ml BSA at 37°C for 5
min. Chemosensor 1 (25–300 nM) was then added and the initial velocity was measured at 520
nm over the first 2 min. The curve was fit to the Hill equation (IGOR Pro) where n = 1 to yield
the Michaelis-Menten equation. The Km and Vmax could then be determined. For kcat (kcat (kcat
= Vmax/[enzyme]), the fluorescence units with time (at saturation) was converted to product
produced with time to obtain Vmax (nM/s). Since MGMT is not a turnover enzyme, the maxi-
mum of product produced is equal to the concentration of enzyme used. Also note that “kcat”
values are technically measurements of inactivation and not catalysis; thus “kinact” is more
accurate [24].
Supporting Information
S1 File. Supporting Information for Fluorogenic Real-time Reporters of DNA Repair by
MGMT, a Clinical Predictor of Antitumor Drug Response.
(DOC)
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